Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 01 03 2018
revised: 29 07 2018
accepted: 10 10 2018
pubmed: 17 10 2018
medline: 28 2 2020
entrez: 17 10 2018
Statut: ppublish

Résumé

Targeted therapies that use the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in the regulation of protein homeostasis and are potential targets for overcoming chemoresistance. We identified FKBP7, a prolyl-peptidyl isomerase overexpressed in docetaxel-resistant and in cabazitaxel-resistant prostate cancer cells. This is the first study to characterize the function of human FKBP7 and explore its role in cancer. We discovered that FKBP7 was upregulated in human prostate cancers and its expression correlated with the recurrence observed in patients receiving docetaxel. Targeting FKBP7 or the eIF4G-containing eIF4F translation initiation complex could be novel therapeutic strategies to eradicate taxane-resistant prostate cancer cells.

Identifiants

pubmed: 30322877
pii: 1078-0432.CCR-18-0704
doi: 10.1158/1078-0432.CCR-18-0704
doi:

Substances chimiques

Antineoplastic Agents 0
Bridged-Ring Compounds 0
Calcium-Binding Proteins 0
Eukaryotic Initiation Factor-4F 0
FKBP7 protein, human 0
RNA, Small Interfering 0
Taxoids 0
taxane 1605-68-1
Tacrolimus Binding Proteins EC 5.2.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

710-723

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Marine F Garrido (MF)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Nicolas J-P Martin (NJ)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Matthieu Bertrand (M)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Catherine Gaudin (C)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Frédéric Commo (F)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Nassif El Kalaany (N)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Nader Al Nakouzi (N)

Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Ladan Fazli (L)

Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Elaine Del Nery (E)

Institut Curie, PSL Research University, Paris, France.
Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.

Jacques Camonis (J)

Institut Curie, PSL Research University, Paris, France.
Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.
INSERM, U830, Paris, France.

Franck Perez (F)

Institut Curie, PSL Research University, Paris, France.
Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.
CNRS, UMR144, Paris, France.

Stéphanie Lerondel (S)

PHENOMIN-TAAM, CIPA, CNRS UPS44, Orléans, France.

Alain Le Pape (A)

PHENOMIN-TAAM, CIPA, CNRS UPS44, Orléans, France.

Daniel Compagno (D)

Molecular and Functional Glyco-Oncology Lab, IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales-Universidad de Buenos Aires, CABA, Argentina.

Martin Gleave (M)

Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Yohann Loriot (Y)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Laurent Désaubry (L)

CNRS UMR7200, Strasbourg University, Illkirch, France.

Stéphan Vagner (S)

Institut Curie, PSL Research University, Paris, France.
CNRS, UMR3348, Orsay, France.

Karim Fizazi (K)

Prostate Cancer Group, INSERM UMR981, Villejuif, France.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Anne Chauchereau (A)

Prostate Cancer Group, INSERM UMR981, Villejuif, France. anne.chauchereau@gustaveroussy.fr.
Univ Paris-Sud, UMR981, Villejuif, France.
Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH